Actualités Myogen - MYOG | Actions NASDAQ

Gilead Sciences Completes Acquisition of Myogen

Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it has completed its acquisition of Myogen, Inc. (Nasdaq:MYOG). On...

Darusentan Data to Be Presented at AHA 2006 -- Chicago

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small...

Darusentan Data to Be Presented at ISH 2006 -- Fukuoka, Japan

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small...

Four Ambrisentan Studies to Be Presented at Chest 2006 -- Salt Lake City

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small...

Seven Summits Research Releases Comments on GOOG, ABX, HET, CBS, and MYOG

CHICAGO, Oct. 2 /PRNewswire/ -- Seven Summits Research Releases NewsBites on key stocks. Seven Summits Strategic Investments NewsBites are...

Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion

Gilead Sciences, Inc. (Nasdaq:GILD) and Myogen, Inc. (Nasdaq:MYOG) announced today that the companies have signed a definitive...

Myogen to Present at the UBS Global Life Sciences Conference

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule...

Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule...

The American Lung Association and Myogen Announce Pulmonary Arterial Hypertension Educational Partnership

The American Lung Association and Myogen, Inc. (Nasdaq: MYOG) today announced that they will collaborate on a new public awareness initiative to...

Myogen Reports 2006 Second Quarter Results

Myogen, Inc. (Nasdaq:MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics...

Myogen to Announce 2006 Second Quarter Results on August 7, 2006

Myogen, Inc. (Nasdaq:MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics...

Myogen Announces Extension of Drug Discovery Collaboration

Myogen, Inc. (NASDAQ: MYOG) today announced a two-year extension of its research collaboration with Novartis for the discovery and development of...

Myogen to Present at the Goldman Sachs Global Healthcare Conference

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule...

Myogen Initiates Phase 3 Clinical Trial of Darusentan in Patients with Resistant Hypertension

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule...

Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego; Significant Improvement in Six-Minute Walk Distance an

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule...

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Myogen (MYOG)

Votre Hub pour des idées et discussions en direct en temps réel

MYOG Actualités

Gilead Sciences Completes Acquisition of Myogen

Darusentan Data to Be Presented at AHA 2006 -- Chicago

Darusentan Data to Be Presented at ISH 2006 -- Fukuoka, Japan

Four Ambrisentan Studies to Be Presented at Chest 2006 -- Salt Lake City

Seven Summits Research Releases Comments on GOOG, ABX, HET, CBS, and MYOG

Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion

Myogen to Present at the UBS Global Life Sciences Conference

Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension

The American Lung Association and Myogen Announce Pulmonary Arterial Hypertension Educational Partnership

Myogen Reports 2006 Second Quarter Results

Myogen to Announce 2006 Second Quarter Results on August 7, 2006

Myogen Announces Extension of Drug Discovery Collaboration

Myogen to Present at the Goldman Sachs Global Healthcare Conference

Myogen Initiates Phase 3 Clinical Trial of Darusentan in Patients with Resistant Hypertension

Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego; Significant Improvement in Six-Minute Walk Distance an

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Myogen (MYOG) Actualités

Myogen (MYOG)

Votre Hub pour des idées et discussions en direct en temps réel

MYOG Actualités

Gilead Sciences Completes Acquisition of Myogen

Darusentan Data to Be Presented at AHA 2006 -- Chicago

Darusentan Data to Be Presented at ISH 2006 -- Fukuoka, Japan

Four Ambrisentan Studies to Be Presented at Chest 2006 -- Salt Lake City

Seven Summits Research Releases Comments on GOOG, ABX, HET, CBS, and MYOG

Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion

Myogen to Present at the UBS Global Life Sciences Conference

Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension

The American Lung Association and Myogen Announce Pulmonary Arterial Hypertension Educational Partnership

Myogen Reports 2006 Second Quarter Results

Myogen to Announce 2006 Second Quarter Results on August 7, 2006

Myogen Announces Extension of Drug Discovery Collaboration

Myogen to Present at the Goldman Sachs Global Healthcare Conference

Myogen Initiates Phase 3 Clinical Trial of Darusentan in Patients with Resistant Hypertension

Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego; Significant Improvement in Six-Minute Walk Distance an

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres